CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: SKIN CANCER TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Melanoma
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Non-Melanoma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Non-Melanoma Skin Cancer Treatment Market by Type
4.3.4.1 Basal Cell Carcinoma Market size and forecast, by region
4.3.4.2 Squamous Cell Carcinoma Market size and forecast, by region
4.3.4.3 Others Market size and forecast, by region
CHAPTER 5: SKIN CANCER TREATMENT MARKET, BY THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Immunotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Targeted Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Chemotherapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: SKIN CANCER TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.2.1 North America Non-Melanoma Skin Cancer Treatment Market by Type
7.2.3 North America Market size and forecast, by Therapy
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Therapy
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Therapy
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Therapy
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.2.1 Europe Non-Melanoma Skin Cancer Treatment Market by Type
7.3.3 Europe Market size and forecast, by Therapy
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Therapy
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Therapy
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Therapy
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Therapy
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Therapy
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Therapy
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.2.1 Asia-Pacific Non-Melanoma Skin Cancer Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Therapy
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Therapy
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Therapy
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Therapy
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Therapy
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Therapy
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Therapy
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.2.1 LAMEA Non-Melanoma Skin Cancer Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Therapy
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Therapy
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Therapy
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Therapy
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Therapy
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Amgen Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bristol-Myers Squibb
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 F. Hoffmann-La Roche
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Glaxosmithkline plc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 LEO Pharma
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck KGaA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Regeneron Pharmaceuticals, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sun Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
TABLE 1. GLOBAL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. SKIN CANCER TREATMENT MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 3. SKIN CANCER TREATMENT MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. SKIN CANCER TREATMENT MARKET, FOR NON-MELANOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 5. SKIN CANCER TREATMENT MARKET FOR NON-MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 7. SKIN CANCER TREATMENT MARKET, FOR BASAL CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 8. SKIN CANCER TREATMENT MARKET, FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 9. SKIN CANCER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. GLOBAL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 11. SKIN CANCER TREATMENT MARKET, FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 12. SKIN CANCER TREATMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. SKIN CANCER TREATMENT MARKET, FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 14. SKIN CANCER TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. SKIN CANCER TREATMENT MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 16. SKIN CANCER TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. GLOBAL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 18. SKIN CANCER TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 19. SKIN CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. SKIN CANCER TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. SKIN CANCER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. SKIN CANCER TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. SKIN CANCER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. SKIN CANCER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. U.S. SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 31. U.S. SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 32. U.S. SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. CANADA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. CANADA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 35. CANADA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 36. MEXICO SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. MEXICO SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 38. MEXICO SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 39. EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. EUROPE NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 41. EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 42. EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. EUROPE SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 44. GERMANY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. GERMANY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 46. GERMANY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. FRANCE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. FRANCE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 49. FRANCE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. UK SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. UK SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 52. UK SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 53. ITALY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. ITALY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 55. ITALY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. SPAIN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. SPAIN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 58. SPAIN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 67. JAPAN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 68. JAPAN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 69. JAPAN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. CHINA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. CHINA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 72. CHINA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. INDIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 74. INDIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 75. INDIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 76. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 79. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 82. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 85. LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 86. LAMEA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 87. LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 88. LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. LAMEA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 90. BRAZIL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 91. BRAZIL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 92. BRAZIL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 96. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 99. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 102.AMGEN INC.: COMPANY SNAPSHOT
TABLE 103.AMGEN INC.: OPERATING SEGMENTS
TABLE 104.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 105.AMGEN INC.: NET SALES,
TABLE 106.AMGEN INC.: KEY STRATERGIES
TABLE 107.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 108.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 109.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 110.BRISTOL-MYERS SQUIBB: NET SALES,
TABLE 111.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
TABLE 112.F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
TABLE 113.F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
TABLE 114.F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 115.F. HOFFMANN-LA ROCHE: NET SALES,
TABLE 116.F. HOFFMANN-LA ROCHE: KEY STRATERGIES
TABLE 117.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 118.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 119.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 120.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 121.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 122.LEO PHARMA: COMPANY SNAPSHOT
TABLE 123.LEO PHARMA: OPERATING SEGMENTS
TABLE 124.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 125.LEO PHARMA: NET SALES,
TABLE 126.LEO PHARMA: KEY STRATERGIES
TABLE 127.MERCK KGAA: COMPANY SNAPSHOT
TABLE 128.MERCK KGAA: OPERATING SEGMENTS
TABLE 129.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 130.MERCK KGAA: NET SALES,
TABLE 131.MERCK KGAA: KEY STRATERGIES
TABLE 132.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 133.NOVARTIS AG: OPERATING SEGMENTS
TABLE 134.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 135.NOVARTIS AG: NET SALES,
TABLE 136.NOVARTIS AG: KEY STRATERGIES
TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
TABLE 138.PFIZER INC.: OPERATING SEGMENTS
TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 140.PFIZER INC.: NET SALES,
TABLE 141.PFIZER INC.: KEY STRATERGIES
TABLE 142.REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 143.REGENERON PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 144.REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 145.REGENERON PHARMACEUTICALS, INC.: NET SALES,
TABLE 146.REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 147.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 148.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 149.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 150.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 151.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
